ABSTRACT
INTRODUCTION
The management of mental health problems constitutes a significant part of general practice (GP) . and data provided by the Australian Institute of Health and Welfare (AIHW) estimated that approximately 12.1% of GP encounters in 2011-12 involved a component of mental health (Australian Institute of Health and Welfare, 2013) . This translates to almost 15.0 million mental health-related GP encounters annually and the most common management option was to prescribe, supply or recommend medication (Australian Institute of Health and Welfare, 2013) . There were 31.1 million prescriptions dispensed for mental health-related medicines subsidised under the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) in 2012-13, accounting for 11.4% of all prescriptions (Australian Institute of Health and Welfare, 2014) . GPs generated 86% of prescriptions while psychiatrists and non-psychiatric specialists prescribed 8% each; the majority of prescriptions were for antidepressant medicines (65.9%) followed by anxiolytics (12.2%), antipsychotics (10.6%) and hypnotics and sedatives (8.7%) (Australian Institute of Health and Welfare, 2014) . 6 self-efficacy, collaboration, change, change management, practice change, barriers, facilitators.
RESULTS
Four systematic reviews investigating the provision of medication management at primary care level and ten randomised controlled trials of mental health services provided by pharmacists were identified. A number of reviews outlining the impact of community pharmacy based disease state or medicines management services were also evaluated as well as literature on the Australian community pharmacy setting.
Community pharmacy mental health professional services
Four systematic reviews were undertaken investigating the role of community pharmacy delivering mental healthcare services:
1. Bell et al. (2005) described pharmacy services to community based mental health consumers living at home or in residential care as well as clinical pharmacy services to other health professionals. This review provides evidence that pharmacists can contribute to optimising the use of medications in the community setting.
2. Rubio-Valera et al. (2011) focussed on pharmacist interventions to improve consumer adherence to antidepressant therapy. The authors suggested that a pharmacist intervention is effective in the improvement of consumer adherence to antidepressants but acknowledged that data were still limited.
3. Chong et al. (2011) reviewed 26 studies with interventions that improved both adherence and depression outcomes. Several of the studies were in primary care settings and the review concluded that educational interventions alone were ineffective and that there was evidence for the need for multifaceted interventions including educational, behavioural, affective and provider targeted strategies.
4. Al-Jumah and Qureshi (2012) published a systematic review of the impact of pharmacist interventions on consumer adherence to antidepressants and patientreported outcomes. The review concluded that pharmacists' interventions were effective in the improvement of adherence to antidepressants.
The systematic reviews largely focussed on improvements in adherence to medication and consumer/patient outcomes relating to depressive symptoms. These reviews are important as they lay the foundation for understanding what may and may not work for mental health consumers provided with medication management services by community pharmacists. From these systematic reviews eight RCTs were identified. Another two RCTs were added through a further review: (1) a PhD thesis by Harris (2005) from Nottingham University describes a pilot RCT of community pharmacists and key workers undertaking joint domiciliary visits providing pharmaceutical care and adherence support to older adults with mental health problems, and (2) a Spanish study reports on adherence and depression outcomes in patients newly initiated on antidepressants (Rubio-Valera et al., 2012) . In total, ten community pharmacy based mental health RCTs were identified. An overview of these studies is provided in Table 1 .
The RCTs and systematic reviews provide valuable lessons to be considered in the development of future community pharmacy mental healthcare services. A number of themes emerged that could result in service delivery shortcomings namely: focus on participants newly initiated on antidepressants; focus on adherence as outcome; focus on delivering "information" and/or "education" over behaviour change strategies; and lack of Australian community pharmacy mental health role 8 focus on collaboration with other health professionals. Each of these is described in more detail below.
Focus on participants newly initiated on antidepressants
The large majority of the community pharmacy-based mental health RCTs involved consumers who were newly initiated on antidepressants (Brook et al., 2003; Bultman & Svarstad, 2002; Capoccia et al., 2004; Finley et al., 2003; Rickles et al., 2005; Rubio-Valera et al., 2012) . The first four to six weeks of therapy is a crucial time both from an adherence perspective and for monitoring response to therapy (Best Practice Advocacy Centre, 2009).
However, this period may not be ideal for a medication management intervention that requires consumer time and commitment for the following reasons: coping with a new diagnosis, acute symptoms of illness, and information overload. Also, mental health consumers, like consumers with other chronic conditions, have medication management needs throughout their treatment journey and not only when initiated on new medicines.
Research has indeed highlighted that about 50% of people with long-term conditions are not adherent, irrespective of the illness or setting (World Health Organization, 2003) .
Medication management services should therefore target all consumers with chronic conditions throughout their journey.
Focus on adherence as outcome
All of the studies focussed on adherence as the key outcome with indirect measures such as pharmacy records or consumer self-reports dominating. However indirect measurements lack robust evidence. Additionally, evidence highlights that concordance, which involves shared decision making between the consumer and the health professional, provides better outcomes (National Institute of Clinical Excellence, 2009).
There is a scarcity of community pharmacy-based literature around medicine concordance and medication management models in mental illness. However, there is literature on other pharmacy settings (e.g. hospital outpatient services) and interventions to improve medication management and mental health outcomes (Al-Jumah & Qureshi, 2012; Bell et al., 2005; Chong et al., 2011; Dolder et al., 2003; Rubio-Valera et al., 2011) . Doctor and nurse led interventions have also been included in broader systematic reviews (Vergouwen et al., 2003) .
Few of the community pharmacy based studies included physical medication aids (e.g. Some of the studies report improvements in clinical outcomes or health-related quality of life without significant differences in adherence rates between the control arm and the intervention (Capoccia et al., 2004; Rubio-Valera et al., 2012) . There is evidence to support the notion that clinical improvement may not be mediated through adherence alone (Chong et al., 2011; Vergouwen et al., 2003) . Disentangling the influence of different interventions on various outcomes is also challenging. A better understanding of the mode of action of different programs is therefore required.
Focus on delivering "information" and/or "education" over behaviour change strategies
The word "coaching" is used in several studies (Brook et al., 2003) whilst the majority of interventions seem to focus more on educational aspects rather than behavioural strategies. There is suggestion that educational activities alone may be ineffective and that combinations of educational, behavioural, affective and provider-targeted strategies are more likely to improve adherence and clinical outcomes (Chong et al., 2011) . Consumer education and medication monitoring appear to be the most commonly employed pharmacist interventions (Al-Jumah & Qureshi, 2012) . Other interventions included monitoring and management of adverse events, provision of written or visual information, and recommendation or implementation of changes or adjustments in medication (RubioValera et al., 2011) .
Educational strategies included information provision largely in oral and written formats but also by telephone and mail (Al-Saffar et al., 2005; Rickles et al., 2005) . Behavioural strategies included telephone follow-up and monitoring, scheduled pharmacy clinic visits, psychotherapy, behavioural prevention plans, and pharmacy refills and checks. Emotional and social support were the most commonly adopted affective strategies, with motivational interviewing being used in fewer studies (Crockett et al., 2006; Rickles et al., 2005) .
Lack of focus on collaboration with other health professionals
There seems to be little collaboration between pharmacists and the general practice team in the community pharmacy based studies and yet this is not the case in models of clinical pharmacists working in advanced primary or secondary care settings (Bell et al., 2005; Chong et al., 2011; Vergouwen et al., 2003) . Few assessments were made by other healthcare professionals as part of the mental health community pharmacy RCTs whilst in some advanced primary care based models, collaborative care is in fact "the intervention" (Vergouwen et al., 2003) . The collaborative practice approach is not reflected in the community pharmacy based RCTs. Provider targeted strategies predominantly included feedback on consumer progress to the GP, although it was missing from the majority of community pharmacy based interventions. Facilitation of referrals to the mental healthcare sector and supervision from specialist psychiatric care were strategies frequently used in the wider primary care literature. This highlights the absence of any integration or collaboration within the community pharmacy RCTs.
Summary
There are limited studies exploring professional service interventions for mental health consumers in community pharmacy. From the evaluation of the limited literature three themes emerged that provide insight into useful strategies in the provision of community pharmacy mental health services namely: pharmacist coaching sessions alongside takehome videos; ongoing monitoring (face-to-face and telephone); and domiciliary visiting service. These themes, discussed below, need to be considered in the development of future service delivery models. However, the majority of studies in systematic reviews relating to medication adherence in mental health were either inpatient (Vergouwen et al., 2003) or primary care based clinical pharmacy services (Bell et al., 2005; Chong et al., 2011) .
As such, the conclusions from these systematic reviews are not entirely applicable to community pharmacy practice.
A number of strategies for professional service delivery seemed to have worked in community pharmacy for mental health consumers. However, there is a dominance of reported research from the US with different health systems to Australia. The findings therefore need to be contextualised for the Australian setting. Nonetheless the learnings from these intervention studies are useful in the development of future Australian community pharmacy mental health professional services and are discussed below.
Pharmacist coaching sessions alongside take-home videos
Three coaching sessions with the addition of a take home video including illness and education-related information improved consumers attitudes to medication and adherence, and the intervention consumers were less depressed and less anxious based on a standard analysis but not on an intention to treat analysis (Brook et al., 2003) . This intervention was more effective in consumers with lower levels of education.
Contrary to these outcomes a similar study in the Netherlands using three education sessions and a take-home video found that consumers had no significant difference in adherence as measured by electronic pill counter (Bosmans et al., 2007) . Further, there were no significant differences in depressive symptom scores. The inclusion of a costeffectiveness analysis led the authors to conclude that "standard care" should be continued.
Short duration education sessions (15min first contact and half that for subsequent visits) covering both medications and mental illness also demonstrated no statistically significant difference in adherence at three and six months nor clinical symptoms or satisfaction with service. Despite this a statistically significant improvement in health-related quality of life was noted.
Ongoing monitoring
Face-to-face medication management monitoring by pharmacists was predictive of consumer satisfaction and self-reported adherence for individuals taking antidepressants for the first time (Bultman & Svarstad, 2002) . One interview focused on how pharmacists covered medication history, knowledge, use and beliefs; the second on pharmacist monitoring and behaviour. Rickles et al. (2005) found that telephone calls by pharmacists to consumers to educate, assess, monitor and make recommendations to improve antidepressant adherence resulted in significantly improved feedback from consumers. There was a 50% improvement in adherence but no statistically significant difference between intervention or control arms in terms of either depressive symptomatology or adherence.
Domiciliary visiting service
A single RCT reported the impact of domiciliary (home) visits by trained community pharmacists in conjunction with key workers. Significant improvements in adherence and reductions in consumers reporting problems taking medicines were reported (Harris, 2005) .
The literature covering professional service interventions for mental health consumers in community pharmacy provide valuable insight into aspects that were proven successful and less successful. Of interest is that nine of the ten RCTs report on interventions developed for depression and no studies reported on more serious mental illnesses (i.e. illness such as schizophrenia) requiring antipsychotic treatment. As consumers on antipsychotics would similarly benefit from pharmacist services and interventions (i.e. management of adverse effects) pharmacists at primary care level could play a critical role in providing care for all consumers with mental illness. However, the literature in this area is limited and the review was therefore expanded to include non-mental health community pharmacy services.
Community pharmacy non-mental health professional services
A number of reviews outlining the impact of community pharmacy based disease state or medicines management services provide understanding into successful interventions and could have some relevance to provision of community pharmacy mental health professional services:
1. Blenkinsopp et al. (2003) undertook a comprehensive overview of the published peer-reviewed evidence relating to community pharmacy based activity in the reduction of risk behaviours and risk factors for coronary heart disease. RCTs and non-randomised experimental studies were identified with positive evaluations in the effectiveness of community pharmacy smoking cessation advice. RCTs and observational studies were identified for community pharmacy-based lipid management. These studies provide evidence of clinical and cost-effectiveness of community pharmacy services in smoking cessation and lipid management in the prevention and management of heart disease. There appears to be significantly more investigation of professional service delivery relating to chronic conditions (such as asthma and cardiovascular disease), and lifestyle interventions such as weight management and smoking cessation than for mental health conditions. In the Australian context considerable research has been generated in these areas with many of the studies funded by the Australian government through the Community Pharmacy Agreements (Department of Health, 2014).
Community pharmacy asthma interventions that involved on-going cycles of assessment, goal-setting, monitoring and medication reviews showed improved adherence outcomes, significant improvements in symptom control, self-efficacy and quality of life (Saini et al., 2007) . Recent research supports these findings but also highlights the importance of face-to-face contact between the pharmacist and consumer (Bereznicki et al., 2013) .
A pharmacist delivered health promotion and screening service for cardiovascular disease risk factors in a rural community with GP engagement reported community benefit through identification and cholesterol testing of at-risk consumers (Hourihan et al., 2003) .
Protocols for improving adherence in hypertensive consumers through comprehensive medicines management packages have resulted in increased consumer education (Lau et al., 2010) , detection and referral of high risk cardiovascular disease consumers (Peterson et al,, 2010) . A pilot study outlining a holistic approach to multiple cardiovascular disease risk factors reported a significant reduction in risk (McNamara et al., 2012) .
The on-going cycle of assessment, management, monitoring and review provided at regular intervals over a six-month period in community pharmacy for diabetic consumers demonstrated significant improvements in clinical and humanistic outcomes (Krass et al., 2007) . Community pharmacy based weight management programs involving diet advice, behavioural therapy/modification and medication reviews found pharmacies to be accessible locations (Kellow, 2011; Reick et al., 2006) . However consumers' opinions about the role of community pharmacy in weight management showed that some consumers considered pharmacists' motivations to provide advice related to gaining profit from selling a product and expressed concerns about the perceived conflicts of interest as well as lacking expertise and time (Um et al., 2012 ).
An Australian study that examined pharmacists' role in smoking cessation considering current practice and barriers to service provision found that there was a greater service scope for pharmacist involvement in this area (Edwards et al., 2006) . In a New Zealand study the role of community pharmacists in the provision of opiate substitution therapy (OST) was seen as pivotal and integral to addiction treatment (Walters et al., 2012) The findings from the literature of Australian community pharmacists providing medication management services to consumers with chronic physical health conditions, that require significant lifestyle changes such as smoking cessation or weight management, or conditions that have associated stigma such as drug addiction, provide a framework for the expansion of community pharmacy mental health professional services. This is particularly important as there is a dearth of holistic medication management studies about mental health services in the community pharmacy context compared with these other chronic diseases and conditions.
Australian community pharmacy setting
Australian community pharmacy practice has changed throughout the past two decades towards a more significant focus on the provision of professional services to improve consumers' medication management. These changes reflect the international move for the pharmacy profession to accept an increased medication management responsibility.
Community pharmacists' medication management role is important as it has been estimated that 190,000 medication-related hospital admissions occur per year in Australia, an estimated 2-3% of all admissions with estimated costs in excess of $660million (Roughead & Semple, 2009) The overall aim of these services is to improve quality use of medicines and reduce adverse medicine events and all of these professional services could be utilised to improve the medication management of mental health consumers. There has been numerous research evaluating the impact of the home medicine review program which has been in place since 2001 (Gilbert et al. 2002 . The in-pharmacy medication review services and PPIs were only introduced in 2010 with data being collected for assessment.
Community pharmacies participating in Medscheck and Diabetes Medscheck services are required to have a screened area or separate room distinct from the general public area of the pharmacy. This area could be utilised to provide services to mental health consumers given that there may be situations that could be sensitive to discuss and require privacy. This is important as a need for increased community pharmacy privacy and confidentiality requirements for mental health consumers has been identified as a barrier to utilising community pharmacy services (Hattingh et al., 2014) .
Recent research has provided insight into mental health consumers' experiences of community pharmacy. Telephone interviews with 201 mental health consumers and carers from three Australian states explored their experiences of community pharmacy services (Knox et al., 2014) . The results highlighted service gaps as only 36% received verbal advice, the majority were not asked whether they experienced side effects, and 60% reported rarely or never receiving written medicine information. Despite these shortcomings the majority of participants indicated that their expectations were being met and qualitative comments showed that consumers value high-quality services that reflected patient-care.
Semi-structured interviews and focus groups with 74 purposively selected mental health consumers and carers highlighted the importance of positive relationships between pharmacy staff and consumers to reduce stigma experienced in community pharmacies (Knox et al., 2013) . The same study found patient-centred care provided by community pharmacies promoted mental health consumers' and carers' trust in pharmacists and promoted relationship development (Mey et al., 2013) . The findings from these studies provide valuable information about consumers' experiences and needs and expectations of community pharmacy to be considered in the development of mental health professional services.
DISCUSSION
This narrative review identified international studies involving professional service interventions for mental health consumers that could be contextualised for the Australian setting. Although community pharmacy is ideally placed to provide support to mental health consumers, there is a scarcity of literature regarding community pharmacy RCTs in mental health professional service delivery. A search found 10 RCTs, largely from the US, the majority of which were focused on adherence as the main outcome. Multiple measures have been used to assess adherence as well as clinical outcomes, general wellbeing and quality of life in these studies. The interventions within these RCTs included both education alone and education in conjunction with cognitive and behavioural change strategies. Those RCTs identified were conducted with consumers who had recently started on antidepressants and collaboration with GPs and other health professionals was largely missing. Systematic reviews which explored the impact of various pharmacy models on the medication adherence of mental health consumers provide some insight although the conclusions drawn may not necessarily relate to the community pharmacy model as most of these involved hospital inpatient or primary care clinical pharmacy services.
There is a dearth of holistic medication management studies involving mental health in the community pharmacy context compared with other chronic conditions such as asthma, cardiovascular disease, diabetes, obesity/weight management and addiction services for smoking cessation and opiate substitution. It therefore seems timely to explore a larger role for community pharmacy in mental health service delivery in collaboration with GPs and other members of the healthcare team. Newer community pharmacy services provide opportunity for funding of medication management services. Various professional pharmacy service models have developed over recent years to facilitate consumers' medication management at a primary healthcare level (Moullin et al., 2013) .
Australian community pharmacists are in regular contact with mental health consumers and carers through the dispensing of medicines. In addition to dispensing services, pharmacists and pharmacy staff members also provide other services to mental health consumers such as the provision of general healthcare and lifestyle advice, management of minor ailments, medication review services and newer professional services. Pharmacists are therefore in an ideal position to play a more significant role in the medication management of mental health consumers in partnership with other healthcare professionals.
This review focused on medication management mental health services at primary healthcare level and the impact of community pharmacy based disease state management services. The strength of this review lies in the review of both published literature identified through databases and unpublished (grey) literature to contextualise the review in terms of contemporary Australian community pharmacy practice. The combination ensured a comprehensive review of topics amidst the lack of research about the role of community pharmacists in medication management of mental health consumers. However, as this is a narrative rather than a systematic review it is possible that not all studies were incorporated. Another limitation of this review is the comparison to non-mental health pharmacy services. Although these studies provide some insight mental healthcare is unique and pharmacy mental health services will require careful planning.
CONCLUSION
The literature identified a need for community pharmacy to become more involved in the provision of mental health professional services. Information from mental health systematic reviews may not be entirely applicable to community pharmacy although the studies provide a framework that needs to be contextualised for the Australian community pharmacy setting. These include initial face-to-face interactions between pharmacists and mental health consumers and carers as well as ongoing monitoring. A number of strategies seemed to have worked as professional service interventions in community pharmacy for other physical health conditions and in non-mental health areas associated with stigma.
Learnings from these studies could be tailored for mental health service provision. The development of a community pharmacy intervention that focuses on mental health professional services should ideally incorporate elements from the mental health reviews as well as non-mental health studies that have proven successful.
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